A Hong Kong study (80) of 1,236 patients with high-risk hereditary breast and/or ovarian cancers showed that, among 120 deleterious BRCA mutations, 8 (6.7%) were LGRs involving BRCA1 (5/57, or 8.8%) and BRCA2 (3/63, or 4.8%). This evidence concerns the gene BRCA2 and ovarian carcinoma.